郭 杰
(浙江工業(yè)大學藥學院,浙江 杭州 310014)
由于 2,1,3-苯并噻二唑(BTD)具有較強的共平面性、較強的電子親和勢、較好的穩(wěn)定性和較高的氧化點位,對化合物能隙有較好的調節(jié)性[1-2], 因此,2,1,3-苯并噻二唑被廣泛作為有機共軛分子并應用于光電材料領域,在液晶、太陽能電池、離子識別材料、有機發(fā)光二極管、熒光探針等領域有著廣泛的應用[3-5]。在過去幾年中,有越來越多的以2,1,3-苯并噻二唑為結構基元的有機小分子材料的相關報道,在有機太陽能電池領域和有機電致發(fā)光器件中發(fā)揮了很大的作用[6],極大地推動了有機光電材料領域的發(fā)展[7]。
4-甲基-7-芳基-2,1,3-苯并噻二唑是以 3-甲基苯二胺為起始原料制備的,通用方法(Scheme 1):先將化合物1,無水二氯甲烷投入反應容器中,在冰水浴下攪拌30 min,緩慢加入三乙胺,再在0℃下緩慢滴加亞硫酰氯的無水二氯甲烷溶液,將反應在50℃下加熱攪拌5 h,待反應液冷卻后,加入適量水分液,取有機層,用硫酸鈉固體干燥除水,減壓濃縮,柱色譜提純,得到棕色液體化合物2。將化合物2,48%的氫溴酸投入反應容器中,加入液溴的氫溴酸溶液,在120℃下加熱回流16 h,待反應液冷卻后,加碳酸鈉飽和溶液中和反應液,用二氯甲烷萃取,用硫酸鈉固體干燥除水,減壓濃縮,柱色譜提純,得到黃色固體化合物3。將化合物3、芳基硼酸、四三苯基膦鈀、氟化銫投入反應容器中,加入1,4-二氧六環(huán),反應在120℃下加熱回流18 h,待反應液冷卻后,加適量水稀釋反應液,用乙酸乙酯萃取,用硫酸鈉固體干燥除水,減壓濃縮,柱色譜提純,得到化合物4。
Scheme 1 4-甲基-7-芳基-2,1,3-苯并噻二唑合成路線
熔點用SGWRX-4B熔點儀測定,核磁共振儀為Bruker Model AvanceⅢ500 MHz,以TMS為內標。CDCL3和DMSO-d6作為常用的氘代試劑。薄層色譜使用薄層硅膠板(TLC,煙臺江友硅膠),柱層析使用200~300目柱層析硅膠(青島海洋化工)。所用試劑均為分析級。
2.2.1 4-甲基-2,1,3-苯并噻二唑(2)的合成
取500 mL圓底燒瓶,稱取3-甲基苯二胺(10.0 g, 82.0 mmol),無水二氯甲烷(250 mL)加入圓底燒瓶中,在冰水浴下攪拌30 min,緩慢加入三乙胺(45.5 mL,327.9 mmol),再在 0 ℃下緩慢滴加亞硫酰氯(11.9 mL,163.9 mmol)的無水二氯甲烷溶液(50 mL),將反應在50℃下加熱攪拌5 h,待反應液冷卻后,加入水(3×200 mL)分液 3次,取有機層,用無水Na2SO4固體干燥,減壓濃縮,柱色譜提純 (PE/EtOAc=10:1),得到棕色液體化合物 2,11.1 g(90%)。
2.2.2 4-溴-7-甲基-2,1,3-苯并噻二唑 (3)的合成
將化合物 2(11.1 mL, 73.8 mmol)和 48%的氫溴酸(250 mL)加入500 mL圓底燒瓶,再加入液溴(3.8 mL, 74 mmol)的氫溴酸溶液(50 mL),在120℃下加熱回流16 h,待反應液冷卻后,加碳酸鈉飽和溶液中和反應液,用二氯甲烷 (3×200 mL)萃取3次,取有機層,用無水Na2SO4固體干燥,減壓濃縮,柱色譜提純 (PE/EtOAc=30∶1),得到黃色固體化合物3,15.5 g(92%)。1H NMR(500 MHz, CDCl3) δ 7.74(d, J=7.3 Hz, 1H),7.26(dd, J=7.3, 1.3 Hz, 1H), 2.71(s, 2H).
4-Methyl-7-bromo-2,1,3-benzothiadiazole[8]:1H NMR (500 MHz, CDCl3) δ 7.74 (d, J=7.3 Hz,1H),7.26 (dd,J=7.3,1.3 Hz,1H),2.71(s, 2H).
2.2.3 4-甲基-7-芳基-2,1,3-苯并噻二唑(4)的合成
稱取化合物3 (1.1 g,5.0 mmol)、芳基硼酸(6.0 mmol)、四三苯基膦鈀(577.5 mg, 0.5 mmol)、氟化銫 (1.5 g,10.0 mmol)置于100 mL耐壓管中,加入 1,4-二氧六環(huán)(30 mL),反應在 120 ℃下加熱回流18 h,待反應液冷卻后,加水(100 mL)稀釋反應液,用乙酸乙酯(3×50 mL)萃取 3次,取有機層,用硫酸鈉固體干燥,減壓濃縮,柱色譜提純 (PE/EtOAc=30∶1),得到化合物 4。具體收率見Scheme 2。
4-methyl-7-phenyl-2,1,3-benzothiadiazole (4a):1H NMR (500 MHz, CDCl3) δ 7.92(d,J=7.0 Hz,2H),7.62 (d,J=7.0 Hz,1H),7.54 (t, J=7.7 Hz, 2H), 7.48~7.43 (m, 2H),2.80 (d, J=1.1 Hz, 3H).13C NMR (126 MHz,CDCl3) δ 156.02, 153.50, 137.64, 131.97,130.62, 129.10, 128.56, 128.34, 128.06, 128.00,17.96 (two sp2signal were not observed because of overlapping).
4-methyl-7-(4-methyl)phenyl-2,1,3-benzothiadiazole(4b):1H NMR (500 MHz, CDCl3)δ 7.82 (d,J=8.2 Hz, 2H), 7.60 (d,J=7.0 Hz,1H),7.44 (dd,J=7.0,1.2 Hz,1H),7.37~7.33 (m, 2H), 2.79 (d, J=1.3 Hz, 3H), 2.46(s, 3H).13C NMR (126 MHz, CDCl3) δ 156.01,153.58, 137.94, 134.75, 131.97, 130.22, 129.27,128.95,128.36, 127.57,21.26, 17.92 (two sp2signal were not observed because of overlapping).
4-methyl-7-(4-chloro)phenyl-2,1,3-benzothiadiazole(4c):1H NMR (500 MHz, CDCl3)δ 7.87 (d,J=8.6 Hz,2H),7.60 (d,J=7.0 Hz,1H),7.50 (d,J=8.6 Hz,2H),7.45 (dd,J=7.1,1.2 Hz,1H),2.80 (d,J=1.1 Hz,3H).13C NMR (126 MHz, CDCl3) δ 156.00,153.24,135.99, 134.09, 131.10, 130.63, 130.32, 128.74,128.28, 127.92, 17.98(two sp2signal were not observed because of overlapping).
Scheme 2 化合物4底物拓展
4-methyl-7-(4-fluoro)phenyl-2,1,3-benzothiadiazole(4d):1H NMR (500 MHz, CDCl3)δ 7.90 (dd,J=8.7,5.5 Hz,2H),7.58 (d,J=7.0 Hz, 1H), 7.45 (dd, J=7.1, 1.2 Hz, 1H),7.22 (t, J=8.7 Hz, 2H), 2.80 (d, J=1.1 Hz,3H).13C NMR (126 MHz,CDCl3) δ 162.72 (JC-F=247.8 Hz), 155.99, 153.39, 133.64 (JC-F=3.3 Hz), 130.86, 130.74 (JC-F=8.1 Hz), 130.74,128.30, 127.83, 115.50 (JC-F=21.4 Hz), 17.94(two sp2signal were not observed because of overlapping).
4-methyl-7-(4-methoxy)phenyl-2,1,3-benzothiadiazole(4e):1H NMR (500 MHz, CDCl3) δ 7.88 (d, J=8.8 Hz, 2H), 7.56 (d, J=7.1 Hz,1H),7.42 (dd,J=7.0,1.2 Hz,1H),7.07(d, J=8.8 Hz, 2H), 3.90 (s, 3H), 2.78 (d, J=1.1 Hz, 3H).13C NMR (126 MHz, CDCl3) δ 159.57, 156.01, 153.54, 131.52, 130.20, 130.10,129.84, 128.38,127.13, 114.01,55.35, 17.87(two sp2signal were not observed because of overlapping).
4-methyl-7-(2-chloro)phenyl-2,1,3-benzothiadiazole(4f):1H NMR (500 MHz,CDCl3)δ 7.59~7.56 (m, 1H), 7.53 (d, J=6.9 Hz, 1H),7.51~7.49 (m, 1H), 7.47 (dd, J=7.0, 1.2 Hz,1H), 7.42~7.39 (m, 2H), 2.82 (d, J=1.1 Hz,3H).13C NMR (126 MHz, CDCl3) δ 155.41,153.66,136.55, 133.49,131.91, 131.51, 130.04,129.98,129.95,129.45,127.81,126.69,18.00.
4-methyl-7-(2-methoxy)phenyl-2,1,3-benzothiadiazole(4g):1H NMR (500 MHz,CDCl3)δ 7.57 (d,J=6.9 Hz,1H), 7.51 (dd, J=7.5,1.8 Hz,1H),7.45 (dddd,J=7.4,6.1,4.7,1.8 Hz, 2H), 7.15~7.07 (m, 2H), 3.79 (s, 3H),2.80 (d, J=1.2 Hz, 3H).13C NMR (126 MHz,CDCl3) δ 157.02, 155.57, 154.15, 131.57,130.47,129.83, 129.56,129.40, 128.06, 126.73,120.62,111.46,55.66,17.94.
4-methyl-7-(2-trifluoromethyl)phenyl-2,1,3-benzothiadiazole(4h):1H NMR (500 MHz,CDCl3) δ 7.86 (d, J=8.5 Hz, 1H), 7.67 (td, J=7.5, 0.9 Hz, 1H), 7.59 (t, J=7.7 Hz, 1H),7.47 (d, J=7.6 Hz, 1H), 7.44 (s,2H),2.82(s, 3H).13C NMR (126 MHz,CDCl3)δ 155.14,154.32, 136.44, 132.38, 131.54, 131.36, 129.82,129.62, 129.20, 128.27, 127.61, 126.42 (JC-F=5.0 Hz), 124.02 (JC-F=273.6 Hz), 17.97.
4-methyl-7-(3-methoxy)phenyl-2,1,3-benzothiadiazole(4i):1H NMR (500 MHz,CDCl3)δ 7.63 (d, J=7.0 Hz, 1H), 7.52 ~7.48 (m,2H),7.48 ~7.42 (m, 2H),7.02 ~6.98 (m,1H),3.91(s, 3H), 2.80 (d, J=1.1 Hz, 3H).13C NMR(126 MHz, CDCl3) δ 159.71, 156.02, 153.46,138.97, 131.78, 130.76, 129.53, 128.30, 128.03,121.53, 114.99, 113.51, 55.36,17.97.
4-methyl-7-(3-methoxycarbonyl)phenyl-2,1,3-benzothiadiazole(4j):1H NMR (500 MHz,CDCl3) δ 8.57 (t, J=1.8 Hz, 1H), 8.16 (d, J=7.9 Hz, 1H), 8.11(d, J=7.9 Hz, 1H), 7.66 (d,J=7.0 Hz,1H),7.60 (t,J=7.8 Hz, 1H), 7.46(dd, J=7.0, 1.2 Hz, 1H), 3.97 (s, 3H), 2.80(d, J=1.1 Hz, 3H).13C NMR (126 MHz, CDCl3)δ 167.01, 155.98, 153.27, 137.89, 133.58,131.28, 130.79,130.56, 130.10,129.09, 128.63,128.28, 52.25,17.99.
本文探索了一條制備4-甲基-7-芳基-2,1,3-苯并噻二唑的合成工藝路線,以3-甲基苯二胺為起始原料,分子內合環(huán)得到4-甲基-2,1,3-苯并噻二唑,再經溴代反應得到4-甲基-7-溴-2,1,3-苯并噻二唑,再與苯硼酸發(fā)生Suzuki偶聯(lián)反應得到 4-甲基-7-芳基-2,1,3-苯并噻二唑。通過該路線最終得到了15種含有不同取代基4-甲基-7-芳基-2,1,3-苯并噻二唑的衍生物,且收率良好,對光電材料的合成提供了新的前提物質和合成思路,具有良好的工業(yè)應用前景。